Verastem Oncology (VSTM)
9.58
+0.37 (4.02%)
Upcoming Events
Latest Headlines
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
October 22, 2026 7:30 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
October 16, 2026 7:58 AM - StreetInsider
Verastem (VSTM) PT Raised to $14 at Mizuho, 'Reaffirming Potential Best-in-Class Potential'
October 15, 2026 8:04 AM - StreetInsider
Verastem (VSTM) PT Raised to $19 at RBC Capital
October 15, 2026 5:04 AM - StreetInsider
Form 8-K Verastem, Inc. For: Oct 14
October 14, 2026 5:21 PM - SEC Filing
Form 424B5 Verastem, Inc.
October 14, 2026 5:18 PM - SEC Filing
Form 424B5 Verastem, Inc.
October 14, 2026 5:14 PM - SEC Filing
Form 8-K Verastem, Inc. For: Oct 12
October 14, 2026 6:08 AM - SEC Filing
Verastem reports early VS-7375 trial data across multiple cancer types
October 14, 2026 6:04 AM - StreetInsider
Verastem Oncology prices $250M stock and warrant offering
October 14, 2026 6:04 AM - StreetInsider
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
October 14, 2026 6:04 AM - BizWire
Verastem Oncology names Michael Bailey as CEO starting January 2027
October 14, 2026 6:03 AM - StreetInsider
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
October 14, 2026 6:01 AM - BizWire
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Dise
October 14, 2026 6:00 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
October 8, 2026 7:06 AM - StreetInsider
Verastem (VSTM) PT Raised to $19 at B.Riley
October 7, 2026 9:03 AM - StreetInsider
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026 4:02 PM - BizWire
BTIG Reiterates Buy Rating on Verastem (VSTM)
October 5, 2026 8:48 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
October 5, 2026 6:46 AM - StreetInsider
Form 4 Verastem, Inc. For: Sep 30 Filed by: Paterson Dan
October 2, 2026 5:16 PM - SEC Filing
Form 4 Verastem, Inc. For: Sep 30 Filed by: Calkins Daniel
October 2, 2026 5:15 PM - SEC Filing
Verastem presents LGSOC drug data at IGCS 2026 meeting
October 2, 2026 7:30 AM - StreetInsider
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be P
October 2, 2026 7:30 AM - BizWire
Form 144 Verastem, Inc. Filed by: Paterson Dan
October 1, 2026 6:56 PM - SEC Filing
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Rec
September 28, 2026 4:10 PM - BizWire
Verastem (VSTM) Reiterated at Overweight by Cantor Fitzgerald as Key Readout is Near
September 28, 2026 7:05 AM - StreetInsider
Verastem data on ovarian cancer drug combo set for IGCS 2026
September 24, 2026 8:31 AM - StreetInsider
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
September 24, 2026 8:30 AM - BizWire
Form 4 Verastem, Inc. For: Sep 21 Filed by: Calkins Daniel
September 23, 2026 8:10 PM - SEC Filing
Wolfe Research Starts Verastem (VSTM) at Outperform
September 17, 2026 5:03 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
September 14, 2026 7:35 AM - StreetInsider
Form SCHEDULE 13G/A Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC
August 14, 2026 10:30 AM - SEC Filing
Verastem (VSTM) PT Lowered to $13 at Mizuho
August 11, 2026 6:35 AM - StreetInsider
Form SCHEDULE 13G Verastem, Inc. Filed by: STATE STREET CORP
August 7, 2026 11:11 AM - SEC Filing
Form 8-K Verastem, Inc. For: Aug 06
August 7, 2026 6:21 AM - SEC Filing
Form 8-K Verastem, Inc. For: Aug 06
August 6, 2026 4:35 PM - SEC Filing
Verastem Oncology (VSTM) Tops Q2 EPS by 12c
August 6, 2026 4:21 PM - StreetInsider
Form 10-Q Verastem, Inc. For: Jun 30
August 6, 2026 4:18 PM - SEC Filing
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
August 6, 2026 4:01 PM - BizWire
Form 4 Verastem, Inc. For: Aug 03 Filed by: Paterson Dan
August 5, 2026 4:37 PM - SEC Filing
Form SCHEDULE 13G Verastem, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
July 31, 2026 10:46 AM - SEC Filing
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BlackRock, Inc.
July 30, 2026 11:20 AM - SEC Filing
Verastem doses first patient in colorectal cancer trial for VS-7375
July 28, 2026 4:01 PM - StreetInsider
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
July 28, 2026 4:01 PM - BizWire
Full Article List
